SMH
·general
·1 hour ago
Why ‘Big Pharma’ isn’t cashing in on the peptide craze
Big pharmaceutical companies remain wary of popular peptides like BPC-157 and Melanotan-II, citing safety and profitability concerns. Novo Nordisk's Ana Svensson highlighted that these substances lack rigorous safety evaluations required for drug development. As a result, companies are hesitant to invest in a lengthy approval process for products that do not meet regulatory standards.
Summary by Glance · SMH
Newer
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI